Novel approaches to the treatment of hepatitis C virus infection

Antiviral Chemistry and Chemotherapy

Volumn 11, Issue 2, 2000, Pages 79-96

  Dymock, Brian W ^a   Jones, Philip S ^a   Wilson, Francis X ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Helicase; Hepatitis C virus; Interferon; Peptide inhibitors; RNA dependent RNA polymerase; Serine protease

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BENZAMIDE DERIVATIVE; CERULENIN; ENZYME INHIBITOR; GLIOTOXIN; HELICASE; INOSINATE DEHYDROGENASE; INTERFERON; MERIMEPODIB; PROTEINASE; PROTEINASE INHIBITOR; RD3 4078; RD3 4082; RD4 6193; RD4 6205; RD4 6250; RIBAVIRIN; SCH 351633; SCH 68631; SERINE PROTEINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG TARGETING; HEPATITIS C; HUMAN; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

EID: 0034054051     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020001100201     Document Type: Review

References (166)

1. Agnello V, Abel G, Elfahal M, Knight GB & Zhang Q-X (1999) Hepatitis C virus and other Flaviridae viruses enter cells via low density lipoprotein receptor. Proceedings of the National Academy of Sciences, USA 96:12766-12771.
2. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K & Miyano M (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417-1426.
3. Al RH, Xie Y, Wang Y & Hagedorn CH (1998) Expression of recombinant hepatitis C virus non-structural protein 5B in Escherichia coli. Virus Research 53:141-149.
4. Alper J (1993) Oligonucleotides surge into clinical trials. Bio/Technology 11:1225.
5. Alt M, Renz R, Hofschneider PH, Paumgartner G & Caselmann WH (1995) Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 22:707-717.
6. Alt M, Renz R, Hofschneider PH & Caselmann WH (1997) Core specific anitisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation. Archives of Virology 142:589-599.
7. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA & Margolis HS (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine 341:556-562.
8. Asabe S-I, Tanji Y, Satoh S, Kaneko T, Kimura K & Shimotohno K (1997) The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation. Journal of Virology 71:790-796.
9. Attwood MR, Hurst DN, Jones PS, Kay PB, Raynham TM & Wilson FX (1998) Antiviral peptide derivatives. PCT WO98/22496.
10. Attwood MR, Bennett JM, Campbell AD, Canning GGM, Carr MG, Conway E, Dunsdon RM, Greening JR, Jones PS, Kay PB, Handa BK, Hurst DN, Jennings NS, Jordan S, Keech E, O'Brien MA, Overton HA, King-Underwood J, Raynham TM, Stenson KP, Wilkinson CS, Wilkinson TCI & Wilson FX (1999a) The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase. Antiviral Chemistry and Chemotherapy 10:259-273.
11. Attwood M, Hurst D, Jones P, Kay P, Raynham T & Wilson F (1999b) Preparation and use of amino acid derivatives as anti-viral agents. German Patent DE19914474.
12. Bailon PS & Palleroni AV (1997) Polyethylene glycol conjugates of α-interferons. European Patent 809996.
13. Barbato G, Cicero DO, Nardi MC, Steinkuhler C, Cortese R, De Francesco R & Bazzo R (1999) The solution structure of the N-terminal protease domain of the hepatitis C virus (HCV) NS3 protein provides new insight into its activation and catalytic mechanism. Journal of Molecular Biology 289:371-384.
14. Bartenschlager R (1997) Molecular targets in inhibition of hepatitis C virus replication. Antiviral Chemistry and Chemotherapy 8:281-301.
15. Bartenschlager R, Ahlborn-Laake L, Mous J & Jacobsen H (1993) Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. Journal of Virology 67:3835-3844.
16. Bartenschlager R, Lohmann V, Wilkinson T & Koch JO (1995) Complex formation between the N S3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. Journal of Virology 69:7519-7528.
17. Behrens S-E, Tomei L & De Francesco R (1996) Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO Journal 15:12-22.
18. Berenguer M & Wright TL (1998) Hepatitis B and C viruses: molecular identification and targeted antiviral therapies. Proceedings of the Association of American Physicians 110:98-112.
19. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R & Rey FA (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proceedings of the National Academy of Sciences, USA 96:13034-13039.
20. Cheng J-C, Chang M-F & Chang SC (1999) Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3′ end of the viral RNA. Journal of Virology 73:7044-7049.
21. Chu M, Mierzwa R, Truumees I, King A, Patel M, Berrie R, Hart A, Butkiewicz N, DasMahapatra B, Chan T-M & Puar MS (1996) Structure of Sch 68631: a new HCV proteinase inhibitor from Streptomyces sp. Tetrahedron Letters 37:7229-7232.
22. Chu M, Mierzwa R, He L, King A, Patel M, Pichardo J, Hart A, Butkiewicz N & Puar MS (1999) Isolation and structure of Sch 68631: a novel (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum. Bioorganic and Medicinal Chemistry Letters 9:1949-1952.
23. Cicero DO, Barbato G, Koch U, Ingallinella P, Bianchi E, Nardi MC, Steinkuhler C, Cortese R, Matassa V, De Francesco R, Pessi A & Bazzo R (1999) Structural characterisation of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. Journal of Molecular Biology 289:385-396.
24. Clarke B (1997) Molecular virology of hepatitis C virus. Journal of General Virology 78:2397-2410.
25. Clemens MJ & Elia A (1997) The double-stranded RNA-dependant protein kinase PKR: structure and function. Journal of Interferon and Cytokine Research 17:503-524.
26. Cohen J (1999a) The scientific challenge of hepatitis C. Science 285:26-30.
27. Cohen J (1999b) Public health effort unwittingly spread HCV. Science 285:27.
28. Cuthbert JA (1994) Hepatitis C: progress and problems. Clinical Microbiology Reviews 7:505-532.
29. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling M-H & Albrecht JK (1998) Interferon-alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England Journal of Medicine 339:1493-1499.
30. De Francesco R, Behrens S-E, Tomei L, Altamura S & Jiricny J (1996) RNA-dependent RNA polymerase of hepatitis C virus. Methods in Enzymology 275:58-67.
31. Delvecchio A & Zhong W (1999) Screening methods using an ATPase protein from a virus of the Flaviridae family. PCT WO99/01582.
32. Diana GD & Bailey TR (1997) Compounds, compositions and methods for treatment of hepatitis C. US Patent 5,633,388.
33. Diana GD, Bailey TR & Nitz TJ (1997) Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C. PCT WO97/36554.
34. Dimasi N, Martin F, Volpari C, Brunetti M, Biasiol G, Altamura S, Cortese R, De Francesco R, Steinkuhler C & Sollazzo M (1997) Characterisation of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. Journal of Virology 71:7461-7469.
35. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG & Rice CM (1994) Formation and intracellular localisation of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and sindbis viruses. Journal of Virology 68:6147-6160.
36. Edwards PD & Bernstein PR (1994) Synthetic inhibitors of elastase. Medicinal Research Reviews 14:127-194.
37. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Maruno F & Sato C (1995) Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. Journal of Clinical Investigation 96:224-230.
38. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Maruno F & Sato C (1996) Mutations in the non-structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New England Journal of Medicine 334:77-81.
39. Errington W, Wardell AD, McDonald S, Goldin RD & McGarvey J (1999) Subcellular localisation of NS3 in HCV-infected hepatocytes. Journal of Medical Virology 59:456-462.
40. Ferrari E, Wright-Minogue J, Fang JWS, Baroudy BM, Lau JYN & Hong Z (1999) Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. Journal of Virology 73:1649-1654.
41. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S & McKeating JA (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. Journal of Virology 73:6235-6244.
42. Fournier C, Sureau C, Coste J, Ducos J, Pageaux G, Larrey D, Domergue J & Maurel P (1998) In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. Journal of General Virology 79:2367-2374.
43. Frangeul L, Cresta P, Perrin M, Lunel F, Opolon P, Agut H & Huraux J-M (1998) Mutations in the NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy for most common European hepatitis C virus genotypes. Hepatology 28:1674-1679.
44. Galderisi U, Cascino A & Giordano A (1999) Antisense oligonucleotides as therapeutic agents. Journal of Cellular Physiology 181:251-257.
45. Gale MJ, Jr., Korth MJ, Tang NM, Tan S-L, Hopkins DA, Dever TE, Polyak SJ, Gretch DR & Katze MG (1997) Evidence that hepatitis C virus resistant to interferon is mediated through repression of the PKR protein kinase by the non-strucutral 5A protein. Virology 230:217-227.
46. Gallinari P, Paolini C, Brennan D, Nardi C, Steinkuhler C & De Francesco R (1999) Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A. Biochemistry 38:5620-5632.
47. Galun E, Burakova T, Ketzinel M, Lubin I, Shezen E, Kahana Y, Eid A, Ilan Y, Rivkind A, Pizov G, Shouval D & Reisner Y (1995) Hepatits C virus viremia in SCID BNX mouse chimera. Journal of Infectious Diseases 172:25-30.
48. Gilbert BE & Knight V (1986) Biochemistry and clinical applications of ribavirin. Antimicrobial Agents and Chemotherapy 30:201-205.
49. Gish RG (1999) Future directions in the treatment of patients with chronic hepatitis C virus infection. Canadian Journal of Gastroenterology 13:57-62.
50. Gorbalenya AE, Koonin EV, Donchenko AP & Blinov VM (1989) Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes. Nucleic Acids Research 17:4713-4730.
51. Grakoui A, McCourt DW, Wychowski C, Feinstone SM & Rice CM (1993) A second hepatitis C virus-encoded proteinase. Proceedings of the National Academy of Sciences, USA 90:10583-10587.
52. Gwack Y, Kim DW, Han JH & Choe J (1997) DNA helicase activity of the hepatitis C virus nonstructural protein 3. European Journal of Biochemistry 250:47-54.
53. Hahm B, Han DS & Back SH (1995) NS3-4A of hepatitis C virus is a chymotrypsin-like protease. Journal of Virology 69:2534-2539.
54. Hansen JL, Long AM & Schultz SC (1997) Structure of the RNA-dependent RNA polymerase of poliovirus. Structure 5:1109-1122.
55. Hart T & Quibell M (1998) Hepatitis C NS3 protease inhibitors. PCT WO98/46630.
56. Heatcote J, Shiffman ML, Cooksley G, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy R, Wright T & Dephamphilis J (1999) Multinational evaluation of the efficacy and safety of once-weekly peginterferon α-2A (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis. Hepatology 30:No.4, Pt 2, AASLD abstract 621.
57. Heilek GM & Peterson MG (1997) A point mutation abolishes the helicase but not the nucleoside triphosphatase activity of hepatitis C virus NS3 protein. Journal of Virology 71:6264-6266.
58. Heinz DW, Hyberts SG, Peng JW, Priestle JP, Wagner G & Grutter MG (1992) Changing the inhibitory specificity and function of the proteinase inhibitor eglin c by site-directed mutagenesis: functional and structural investigation. Biochemistry 31:8755-8766.
59. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K & Shimotohno K (1993) Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. Journal of Virology 67:4665-4675.
60. Hijikata M, Mizushima H, Tanji Y, Komoda Y, Hirowatari Y, Akagi Y, Kato N, Kimura K & Shimotohno K (1993) Proteolytic processing and membrane association of putative non-structural proteins of hepatitis C virus. Proceedings of the National Academy of Sciences, USA 90:10773-10777.
61. Hoofnagle JH & Di Bisceglie AM (1997) The treatment of chronic viral hepatitis. New England Journal of Medicine 336:347-356.
62. Houghton M (1996) Hepatitis C Viruses; pp. 1035-1058. Philadelphia: Lippincott-Raven.
63. Howe AYM, Chase R, Taremi SS, Risano C, Beyer B, Malcolm B & Lau JYN (1999) A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity. Protein Science 8:1332-1341.
64. Hwang SB, Park K-J, Kim Y-S, Sung YC & Lai MMC (1997) Hepatitis C virus NS5B protein is a membrane-associated phosphoprotein with a predominately perinuclear localisation. Virology 227:439-446.
65. Ikeda N, Sakai T, Tsai S, Zao I, Rian H, Yan S, Kai Y & Karai Y (1996) Agent for the prevention and treatment of hepatitis C. Japanese Patent JP-08268890.
66. Ingallinella P, Altamura S, Bianchi E, Taliani M, Ingenito R, Cortese R, De Francesco R, Steinkuhler C & Pessi A (1998) Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimising the cleavage products. Biochemistry 37:8906-8914.
67. Ishido S, Fujita T & Hotta H (1998) Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus. Biochemical and Biophysical Research Communications 244:35-40.
68. Ishii K, Tanaka Y, Yap C-C, Aizaki H, Matsuura Y & Miyamura T (1999) Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding. Hepatology 29:1227-1235.
69. Jackson RC & Weber G (1975) IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 256:331-333.
70. Jin L & Peterson DL (1995) Expression, isolation and characterisation of the hepatitis C virus ATPase/RNA helicase. Archives of Biochemistry and Biophysics 323:47-53.
71. Kai Y, Sao M, Karai Y, Tsukada T & Yanagisawa M (1996) Prevention and treatment of viral diseases. Japanese Patent JP-10101591.
72. Kakiuchi N, Komoda Y, Komoda K, Takeshita N, Okada S, Tani T & Shimotohno K (1998) Non-peptide inhibitors of HCV serine proteinase. FEBS Letters 421:217-220.
73. Kamer G & Argos P (1984) Primary structural comparison of RNA-dependent polymerases from plant, animal and bacterial viruses. Nucleic Acids Research 12:7269-7282.
74. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR & Thomson JA (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355.
75. Kim DW, Kim J, Gwack Y, Han JH & Choe J (1997) Mutational analysis of the hepatitis C virus RNA helicase. Journal of Virology 71:9400-9409.
76. Kim JL, Morgenstern KA, Lin C, Fox T & Thomson JA (1998a) Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex and crystals thereby obtained. PCT WO98/11134.
77. Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C & Caron PR (1998b) Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6:89-100.
78. Kim JL, Morgenstern KA, Caron P & Lin C (1999) Crystals of hepatitis C virus helicase or fragments thereof comprising a helicase binding pocket. PCT WO99/09148.
79. Koonin EV (1991) Similarities in RNA helicases. Nature 352:290.
80. Kruger M, Beger C, Welch PJ, Barber J & Wong-Staal F (1999) Identification of cellular activators of hepatitis C virus internal ribosome entry site (HCV IRES) - mediated translation using a randomized hairpin ribozyme library. Proceedings of the 6th International Symposium on Hepatitis C and Related Viruses, Bethesda, Md., USA, p.31
81. Kumar PKR, Machida K, Urvil PT, Kakiuchi N, Vishnuvardhan D, Shimotohno K, Taira K & Nishikawa S (1997) Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 237:270-282.
82. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F & Sato C (1997) Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-β therapy. Hepatology 25:750-753.
83. Kwong AD, Kim JL, Rao G, Lipovsek D & Raybuck SA (1998a) Hepatitis C virus NS3/4A protease. Antiviral Research 40:1-18.
84. Kwong AD, Kim JL, Rao G, Lipovsek D & Raybuck SA (1998b) Erratum to Hepatitis C virus NS3/4A protease (Antiviral Research 1998; 40:1-18). Antiviral Research 41:67-84.
85. LaPlante SR, Cameron DR, Aubry N, Lefebvre S, Kukolj G, Maurice R, Thibeault D, Lamarre D & Llinas-Brunet M (1999) Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. Journal of Biological Chemistry 274:18618-18624.
86. Le HV, Yao N & Weber PC (1998) Emerging targets in the treatment of hepatitis C virus infection. Emerging Therapeutic Targets 2:125-136.
87. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF & Weber PC (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Structural Biology 6:937-943.
88. Lima WF, Brown-Driver V, Fox M, Hanecak R & Bruice TW (1997) Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. Journal of Biological Chemistry 272:626-638.
89. Lin C & Kim JL (1999) Structure-based mutagenesis study of hepatitis C virus NS3 helicase. Journal of Virology 73:8798-8807.
90. Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, Poirier M, Poupart M-A, Thibeault D, Wernic D & Lamarre D (1998a) Peptide-based inhibitors of the hepatitis C virus serine protease. Biorganic & Medicinal Chemistry Letters 8:1713-1718.
91. Llinas-Brunet M, Bailey M, Deziel R, Fazal G, Gorys V, Goulet S, Halmos T, Maurice R, Poirier M, Poupart M-A, Rancourt J, Thibeault D, Wernic D & Lamarre D (1998b) Studies on the C-terminus of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorganic and Medicinal Chemistry Letters 8:2719-2724.
92. Llinas-Brunet M, Poupart M-A, Rancourt J, Simoneau B, Tsantrizos Y & Wernic D (1999a) Hepatitis C inhibitor peptides. PCT WO99/07733.
93. Llinas-Brunet M, Bailey MD, Halmos T, Poupart M-A & Tsantrizos Y (1999b) Hepatitis C inhibitor peptide analogues. PCT WO99/07734.
94. Lohmann V, Korner F, Herian U & Bartenschlager R (1997) Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. Journal of Virology 71:8416-8428.
95. Lohmann V, Roos A, Korner F, Koch J & Bartenschlager R (1998) Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology 249:108-118.
96. Lohmann V, Korner F, Koch J-O, Herian U, Theilmann L & Bartenschlager R (1999a) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
97. Lohmann V, Overton H & Bartenschlager R (1999b) Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP. Journal of Biological Chemistry 274:10807-10815.
98. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Noomaw EW, Adachi T & Hostomska Z (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331-342.
99. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Margosiak S, Dagostino E & Hostomska Z (1998a) Conformation changes in hepatitis C virus NS3 proteinase during NS4A complexation: correlation with enhanced cleavage and implications for inhibitor design. Fifth International meeting on Hepatitis C virus and related viruses, Venice, Italy, p.151-156.
100. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Margosiak S, Dagostino E & Hostomska Z (1998b) The conformation of hepatitis C virus NS3 proteinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor. Clinical and Diagnostic Virology 10:151-156.
101. Macejak DJ, Jensen KL, Bellon L, Pavco PA & Blatt LM (1999) Inhibition of viral replication by nuclease resistant hammerhead ribozymes directed against hepatitis C virus RNA. Hepatology 30:abstract 995.
102. Magasanik B, Moyed HS & Gehring LB (1957) Enzymes essential for the biosynthesis of nucleic acid guanine; inosine 5′-phosphate dehydrogenase of Aerobacter aerogenes. Journal of Biological Chemistry 226:339-350.
103. th International Conference on Antiviral Research, abstract 65
104. Martin F, Dimasi N, Volpari C, Perrera C, Di Marco S, Brunetti M, Steinkuhler C, De Francesco R & Sollazzo M (1998) Design of selective cglin inhibitors of HCV NS3 proteinase. Biochemistry 37:11459-11468.
105. Mast EE & Alter MJ (1993) Epidemiology of viral hepatitis: an overview. Seminars in Virology 4:273-283.
106. Matsumoto M, Hwang SB, Jeng K-S, Zhu N & Lai MMC (1996) Homotypic interaction and multimerization of hepatitis C core protein. Virology 218:43-51.
107. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling M-H, Cort S & Albrecht JK (1998) Interferon-alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 339:1485-1492.
108. Meurs E, Chong K, Galabru J, Thomas NSB, Kerr IM, Williams BRG & Hovanessian AG (1990) Molecular cloning and characterisation of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62:379-390.
109. Min K-H, Sung Y-C, Choi S-Y & Ahn B-Y (1999) Functional interactions between conserved motifs of the hepatitis C virus RNA helicase protein NS3. Virus Genes 19:33-43.
110. Morgenstern KA, Landro JA, Hsiao K, Lin C, Gu Y, Su MS-S & Thomson JA (1997) Polynucleotide modulation of the protease, nucleoside triphosphate and helicase activities of a hepatitis C virus NS3-4A complex isolated from transfected COS cells. Journal of Virology 71:3767-3775.
111. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ & Perelson AS (1998) Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282:103-107.
112. Neyts J, Meerbach A, McKenna P & De Clercq E (1996) Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus nfections. Antiviral Research 30:125-132.
113. O'Reilly EK & Kao CC (1998) Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. Virology 252:287-303.
114. Overton H, McMillan D, Gillespie F & Mills J (1995) Recombinant baculovirus-expressed NS3 proteinase of hepatitis C virus shows activity in cell-based and in vitro assays. Journal of General Virology 76:3009-3019.
115. Pieroni L, Santolini E, Fipaldini C, Pacini L, Migliaccio G & La Monica N (1997) In vitro study of the NS2-3 protease of hepatitis C virus. Journal of Virology 71:6373-6380.
116. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G & Abrignani S (1998) Binding of hepatitis C virus to CD81. Science 282:938-941.
117. Poordad FF & Gish RG (1999) Developments in hepatitis C during 1997-1999. Expert Opinion on Therapeutic Patents 9:1249-1268.
118. 1 variants of eglin c and of turkey ovomucoid third domain with serine proteinases. Biochemistry 36:1598-1607.
119. Ralston R, Thudium K, Berger K, Kuo C, Gervase B, Hall J, Selby M, Kuo G, Houghton M & Choc Q-L (1993) Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. Journal of Virology 67:6753-6761.
120. Randolph AG & Wang EEL (1996) Ribavirin for the respiratory syncytial virus lower respiratory tract infection. A systematic overview. Archives of Pediatric and Adolescent Medicine 150:942-947.
121. Reed KE, Gorbalenya AE & Rice CM (1998) The NS5A/NS5 proteins of viruses from three genera of the family Flaviridae are phosphorylated by associated serine/threonine kinases. Journal of Virology 72:6199-6206.
122. Reed KE & Rice CM (1999) Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321. Journal of Biological Chemistry 274:28011-28018.
123. Rosen HR & Gretch DR (1999) Hepatitis C virus: current understanding and prospects for future therapies. Molecular Medicine Today 5:393-399.
124. Sali DL, Ingram R, Wendel M, Gupta D, McNemar C, Tsarbopoulos A, Chen JW, Hong Z, Chase R, Risano C, Zhang R, Yao N, Kwong AD, Ramanathan L, Le HV & Weber PC (1998) Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex. Biochemistry 37:3392-3401.
125. Santolini E, Migliaccio G & La Monica N (1994) Biosynthesis and biochemical properties of the hepatitis C virus core protein. Journal of Virology 68:3631-3641.
126. Schinazi RF, Ilan E, Black PL, Yao X & Dagan S (1999) Cell-based and animal models for hepatitis B and C viruses. Antiviral Chemistry and Chemotherapy 10:99-114.
127. Seemuller U, Eulitz M, Fritz H & Strobl A (1980) Structure of the elastase-cathepsin G inhibitor of the leech Hirudo medicinalis. Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie 361:1841-1846.
128. Selby MJ, Glazer E, Masiarz F & Houghton M (1994) Complex processing and protein:protein interactions in the E2:NS2 region of HCV. Virology 204:114-122.
129. Shi ST, Tu H, Gao L, Taylor DR, Yang T, Mircheff AK, Wen Y, Gorbalenya AE, Hwang SB & Lai MMC (1999) Hepatitis C virus NS5A, NS5B and NS4B form a membrane complex with a novel SNARE-like protein. Proceedings of the 6th International Symposium on Hepatitis C and Related Viruses, Bethesda, Md., USA, p.27.
130. Shiffman M, Pockros PJ, Reddy RK, Wright TL, Reindollar R, Fried MW, Perdum III PP & Pedder S (1999) A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon-alfa-2A (PEG) vs standard interferon alfa-2A (IFN) for treatment of chronic hepatitis C. Gastroenterology abstract L0418.
131. Shimizu Y, Yamaji K, Masuho Y, Yokota T, Inoue H, Sudo K, Satoh S & Shimotohno K (1996) Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease. Journal of Virology 70:127-132.
132. Shirotal Y, Yamashita T, Weiping Q, Kaneko S, Kobayashi K & Murakami S (1999) Hepatitis C virus NS5A binds RNA-dependent RNA polymerase (RdRp) NS5B and augments the RdRp activity. Proceedings of the 6th International Symposium on Hepatitis C and Related Viruses, Bethesda, Md., USA, p.29.
133. Shoemaker KR & Thaisrivongs S (1999) Progress in the search for anti-HCV therapeutics. Annual Reports in Medicinal Chemistry 34:129-138.
134. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT & Robins RK (1972) Broad spectrum antiviral activity of Virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
135. th International Conference on Antiviral Research; abstract 76
136. Stein CA, Tonkinson JL & Yakubov L (1991) Phosphorothioate oligodeoxynucleotides - antisense inhibitors of gene expression. Pharmacology and Therapeutics 52:365-384.
137. Stein CA & Cheng YC (1993) Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261:1004-1012.
138. Stempniak M, Hostomska Z, Nodes BR & Hostomsky Z (1997) The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme. Journal of Virology 71:2881-2886.
139. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK & Simon LN (1973) Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad spectrum antiviral agent. Proceedings of the National Academy of Sciences, USA 70:1174-1178.
140. Sudo K, Inoue H, Shimizu Y, Yamaji K, Konno K, Shigeta S, Kaneko T, Yokota T & Shimotohno K (1996) Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. Antiviral Research 32:9-18.
141. Sudo K, Matsumoto Y, Matsushima M, Fujiwara M, Konno K, Shimotohno K, Shigeta S & Yokota T (1997) Novel HCV protease inhibitors: thiazolidine derivatives. Biochemical and Biophysical Research Communications 238:643-647.
142. Sudo K, Matsumoto Y, Matsushima M, Konno K, Shimotohno K, Shigeta S & Yokota T (1997) Novel HCV protease inhibitors: 2,4,6-trihydroxy-3-nitro-benzamide derivatives. Antiviral Chemistry and Chemotherapy 8:541-544.
143. Sudo K, Matsumoto Y, Matsushima M, Konno K, Shimotohno K, Shigeta S & Yokota T (1998) Erratum: novel HCV protease inhibitors: 2,4,6-trihydroxy-3-nitro-benzamide derivatives. Antiviral Chemistry and Chemotherapy 9:186.
144. Sulkowski M, Reindollar R & Yu J (1999) Combination therapy with peginterferon α-2A (PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C (CHC): a phase II open-label study. Hepatology 30:Abstract 145.
145. Suzich JA, Tamura JK, Palmer Hill F, Warrener P, Grakoui A, Rice CM, Feinstone SM & Collett MS (1993) Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. Journal of Virology 67:6152-6158.
146. Tai C-L, Chi W-K, Chen D-S & Hwang L-H (1996) The helicase actitivty associated with hepatitis C virus nonstrucutral protein 3 (NS3). Journal of Virology 70:8477-8484.
147. Takeshita N, Kakiuchi N, Kanazawa T, Komoda Y, Nishizawa M, Tani T & Shimotohno K (1997) An enzyme-linked immunosorbent assay for detecting proteolytic activity of hepatitis C virus proteinase. Analytical Biochemistry 247:242-246.
148. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT & Milovanovic T (1999) Ribavirin polarises human T cell responses towards a type 1 cytokine profile. Journal of Hepatology 30:376-382.
149. Tanji Y, Hijikata M, Satoh S, Kaneko T & Shimotohno K (1995) Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. Journal of Virology 69:1575-1581.
150. Tanji Y, Kaneko T, Satoh S & Shimotohno K (1995) Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. Journal of Virology 69:3980-3986.
151. Taremi SS, Beyer B, Maher M, Yao N, Prosise W, Weber PC & Malcolm BA (1998) Construction, expression and characterization of a novel, fully activated recombinant single-chain hepatitis C virus protease. Protein Science 7:2143-2149.
152. Taylor DR, Shi ST, Romano PR, Barber GN & Lai MMC (1999) Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-110.
153. Tonkinson JL & Stein CA (1993) Antisense nucleic acids -prospects for antiviral intervention. Antiviral Chemistry and Chemotherapy 4:193-200.
154. Tung RD, Harbeson SL, Deininger DD, Murcko MA, Bhisetti GR & Farmer LJ (1998) Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. PCT WO98/17679.
155. Urvil PT, Kakiuchi N, Zhou D-M, Shimotohno K, Kumar PKR & Nishikawa S (1997) Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus. European Journal of Biochemistry 248:130-138.
156. th International Meeting on Hepatitis C Virus and Related Viruses, Venice, Italy, Abstract L14.
157. Walker MA (1999) Hepatitis C virus: an overview of current approaches and progress. Drug Discovery Today 4:518-528.
158. Wardell AD, Errington W, Ciaramella G, Merson J & McGarvey MJ (1999) Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein. Journal of General Virology 80:701-709.
159. Wray SK, Gilbert BE, Noall MW & Knight V (1985) Mode of action of ribavirin: effect of nucleoside pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Research 5:29-37.
160. Wu Z, Yao N, Le HV & Weber PC (1998) Mechanism of autoproteolysis at the NS2-NS3 junction of the hepatitis C virus polyprotein. Trends in Biochemical Sciences 23:92-94.
161. Yamashita T, Kaneko S, Shirota Y, Qin W, Nomura T, Kobayashi K & Murakami S (1998) RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. Journal of Biological Chemistry 273:15479-15486.
162. Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkeuhler C, Tomei L, De Francesco R, Kuo LC & Chen Z (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form. Protein Science 7:837-847.
163. Yao N, Reichert P, Taremi SS, Prosise WW & Weber PC (1999) Molecular views of viral polyprotein processsing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7:1353-1363.
164. Yuan Z-H, Kumar U, Thomas HC, Wen Y-M & Monjardino J (1997) Expression, purification, and partial characterization of HCV RNA polymerase. Biochemical and Biophysical Research Communications 232:231-235.
165. Zhang R, Mui PW & Weber PC (1597) Synthetic inhibitors of hepatitis C virus NS3 protease. PCT WO97/43310.
166. Zimmerman TP & Deeprose RD (1978) Metabolism of 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide and related five-membered heterocycles to 5′-triphosphates in human blood and L5178Y cells. Biochemical Pharmacology 27:709-716.